Sep 14, 2026, 8:45 AM EDT · 11 days ago Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Aug 17, 2026, 8:30 AM EDT · 5 weeks ago Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Aug 13, 2026, 8:30 AM EDT · 6 weeks ago Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
Jul 20, 2026, 8:30 AM EDT · 2 months ago Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Jun 30, 2026, 8:45 AM EDT · 2 months ago Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
May 18, 2026, 8:45 AM EDT · 4 months ago Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
May 14, 2026, 8:30 AM EDT · 4 months ago Dogwood Therapeutics Announces First Quarter 2026 Financial Results
May 7, 2026, 8:30 AM EDT · 4 months ago Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Apr 23, 2026, 9:00 AM EDT · 5 months ago Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
2026-04-15T13:22:56.000Z · 5 months ago Dogwood announces FDA acceptance of SP16 investigational new drug application
Apr 15, 2026, 9:00 AM EDT · 5 months ago Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Mar 18, 2026, 8:30 AM EDT · 6 months ago Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-02T13:35:35.000Z · 7 months ago Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
Feb 2, 2026, 8:30 AM EST · 7 months ago Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
2026-01-15T21:25:14.000Z · 8 months ago Dogwood files to sell 6.43M shares of common stock for holders
Jan 12, 2026, 8:30 AM EST · 8 months ago Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
2025-12-22T15:20:25.000Z · 9 months ago Dogwood announces interim Phase 2b trial results on Halneuron
Dec 22, 2025, 10:15 AM EST · 9 months ago Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dec 2, 2025, 8:00 AM EST · 9 months ago Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
2025-11-11T13:55:32.000Z · 10 months ago Dogwood enrolls first 100 patients in Halneuron Phase 2b trial
Nov 11, 2025, 8:45 AM EST · 10 months ago Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Nov 6, 2025, 8:45 AM EST · 10 months ago Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Oct 30, 2025, 9:15 AM EDT · 11 months ago Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Oct 14, 2025, 8:45 AM EDT · 11 months ago Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
Oct 7, 2025, 8:45 AM EDT · 11 months ago Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
2025-10-01T20:20:32.000Z · 11 months ago Dogwood files to sell 28.04M shares of common stock for holders
2025-09-30T10:15:45.000Z · 12 months ago Dogwood price target raised to $12 from $10 at H.C. Wainwright
2025-09-29T11:20:42.000Z · 12 months ago Dogwood secures royalty free license to develop, commercialize SP16
Sep 29, 2025, 7:15 AM EDT · 12 months ago Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
Sep 3, 2025, 9:15 AM EDT · 1 year ago Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 13, 2025, 9:00 AM EDT · 1 year ago Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
Aug 7, 2025, 1:08 PM EDT · 1 year ago Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Aug 6, 2025, 9:15 AM EDT · 1 year ago Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Jun 3, 2025, 9:15 AM EDT · 1 year ago Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
May 8, 2025, 9:00 AM EDT · 1 year ago Dogwood Therapeutics Announces First Quarter 2025 Financial Results
May 1, 2025, 8:30 AM EDT · 1 year ago Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Apr 11, 2025, 9:15 AM EDT · 1 year ago Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
Mar 31, 2025, 3:45 PM EDT · 1 year ago Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Mar 18, 2025, 8:45 AM EDT · 1 year ago Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Mar 13, 2025, 9:00 AM EDT · 1 year ago Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 7, 2024, 7:05 AM EDT · 1 year ago Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
Aug 8, 2024, 9:15 AM EDT · 2 years ago Virios Therapeutics Announces Second Quarter 2024 Financial Results
Aug 1, 2024, 9:41 AM EDT · 2 years ago Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Jul 23, 2024, 9:15 AM EDT · 2 years ago Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
May 22, 2024, 1:30 PM EDT · 2 years ago Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 19, 2024, 8:53 PM EDT · 2 years ago Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 17, 2024, 4:10 PM EDT · 2 years ago Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 9, 2024, 7:45 AM EDT · 2 years ago Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 2, 2024, 9:15 AM EDT · 2 years ago Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Mar 26, 2024, 9:15 AM EDT · 2 years ago Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Feb 29, 2024, 9:15 AM EST · 2 years ago Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Feb 28, 2024, 9:15 AM EST · 2 years ago Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
Jan 22, 2024, 9:00 AM EST · 2 years ago Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
Jan 2, 2024, 7:05 AM EST · 2 years ago Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
Nov 13, 2023, 7:05 AM EST · 2 years ago Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 6, 2023, 7:05 AM EST · 2 years ago Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023